| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Regulation FD Disclosure
2 November 12, 2026 Legal Notices The information in this slide deck is current as of November 12, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed wi... |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ROCKVILLE, MD, November 3, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced th... |
| 23 Oct 2026 |
8-K: Other Events
2 October 23, 2026 Legal Notices The information in this slide deck is current as of October 23, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position |
| 23 Jul 2026 |
8-K: Other Events
ROCKVILLE, Md., July 23, 2026 — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoin... |
| 08 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Jul 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and liabilities related to its GMP manufacturing operations (the "Purchased Assets"), including it... |
| 20 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
MacroGenics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders on May 19, 2026. A total of 36,744,013 shares of the Company's common stock were present or represented by proxy at the meeting, which represented approximate... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
ROCKVILLE, MD., May 13, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financi... |
| 12 May 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
CONFIDENTIAL TREATMENT REQUESTED: CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVA... |
| 04 May 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
ROCKVILLE, MD, May 4, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it... |
| 08 Apr 2026 |
8-K: Other Events
ROCKVILLE, MD., April 8, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that ... |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
ROCKVILLE, MD., March 9, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an upd... |
| 02 Mar 2026 |
8-K: Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 24 Feb 2026 |
8-K: Other Events
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer |
| 20 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
ROCKVILLE, MD., Nov 12, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for ... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
ROCKVILLE, MD., Aug 14, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financi... |
| 13 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ROCKVILLE, MD, August 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective... |
Loading...